You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (RS)-AMPA hydrobromide
(RS)-AMPA hydrobromide is a more water soluble hydrobromide salt of (RS)-AMPA (Cat. No. 0169).
Technical Data for (RS)-AMPA hydrobromide
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (RS)-AMPA hydrobromide
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||2.67||10 with gentle warming|
Preparing Stock Solutions for (RS)-AMPA hydrobromide
The following data is based on the product molecular weight 267.08. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||37.44 mL||187.21 mL||374.42 mL|
|0.5 mM||7.49 mL||37.44 mL||74.88 mL|
|1 mM||3.74 mL||18.72 mL||37.44 mL|
|5 mM||0.75 mL||3.74 mL||7.49 mL|
Product Datasheets for (RS)-AMPA hydrobromide
References for (RS)-AMPA hydrobromide
References are publications that support the biological activity of the product.
Honore et al (1982) The binding of 3H-AMPA, a structural analogue of glutamic acid, to rat brain membranes. J.Neurochem. 38 173 PMID: 6125564
Krogsgaard-Larsen et al (1980) New class of glutamate agonist structurally related to ibotenic acid. Nature 284 64 PMID: 6101908
Ko et al (2021) Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. Viruses 13 PMID: 33918958
If you know of a relevant reference for (RS)-AMPA hydrobromide, please let us know.
View Related Products by Product Action
Keywords: (RS)-AMPA hydrobromide, (RS)-AMPA hydrobromide supplier, water, soluble, Glutamate, AMPA, Receptors, iGlur, Ionotropic, 1074, Tocris Bioscience
5 Citations for (RS)-AMPA hydrobromide
Citations are publications that use Tocris products. Selected citations for (RS)-AMPA hydrobromide include:
Wasling et al (2012) AMPA receptor activation causes silencing of AMPA receptor-mediated synaptic transmission in the developing hippocampus. PLoS One 7 e34474 PMID: 22485173
Goo et al (2017) Activity-dependent trafficking of lysosomes in dendrites and dendritic spines. J Cell Biol 216 2499 PMID: 28630145
Iskandrani et al (2015) Impact of subanesthetic doses of KA on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons. J Neurosci 29 792 PMID: 25759403
Pierrot et al (2019) Sex-regulated gene dosage effect of PPARα on synaptic plasticity. Life Sci Alliance 2 PMID: 30894406
Chanda et al (2013) Neurons generated by direct conversion of fibroblasts reproduce synaptic phenotype caused by autism-associated neuroligin-3 mutation. J Psychopharmacol 110 16622 PMID: 24046374
Do you know of a great paper that uses (RS)-AMPA hydrobromide from Tocris? Please let us know.
Reviews for (RS)-AMPA hydrobromide
There are currently no reviews for this product. Be the first to review (RS)-AMPA hydrobromide and earn rewards!
Have you used (RS)-AMPA hydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.